MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$64,822K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from issuance of common...
Proceeds from maturities and sal...
Proceeds from sale of in-process...
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Gain on sale of in-process resea...
Payments related to contingent v...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-36,200
-69,005
-62,530
-11,183
Depreciation and amortization
-
-
0
-
Stock-based compensation
13,512
12,806
9,811
9,566
Acquired in-process research and development
-
0
0
-
Change in fair value of derivative liability-Contingent Value Right Liability
-
-
29,769
-
Change in fair value of derivative liability-Forward Contracts
-
-
0
-
Change in fair value of cvr liability
-4,603
-72,469
-
40,399
Gain on sale of in-process research and development asset
40,000
30,000
0
0
Lease rou asset and leasehold improvement impairment loss
-
-
0
-
Loss on disposal of long-lived assets
-
-
0
-
Net accretion of discount on marketable securities
3,093
2,059
2,085
1,350
Interest proceeds from maturities of zero coupon u.s. treasury bills
311
372
61
309
Accounts payable
30
-3,212
1,447
3,745
Deferred revenue
-
-
0
-
Development receivables
-
-
0
-
Operating lease liabilities
-
-
0
-
Amortization of operating lease assets
-
-
0
-
Accrued and other liabilities
-3,428
3,653
3,124
4,411
Other
-
-
0
-
Related party accounts payable
-4
36
-3,956
3,939
Prepaid expenses and other assets
5,608
233
2,880
6,155
Net cash used in operating activities
-69,877
-57,372
-44,578
-37,117
Proceeds from the sale of property plant and equipment
-
-
0
-
Proceeds from maturities and sales of marketable securities
109,439
107,748
94,299
99,191
Cash assumed from asset acquisition of spyre
-
-
0
-
Purchases of marketable securities
447,343
81,167
341,709
74,193
Proceeds from sale of in-process research and development asset
40,000
30,000
0
0
Net cash (used in) provided by investing activities
-297,904
56,581
-247,410
24,998
Proceeds from issuance of private placement, net-Series BNon Voting Convertible Preferred Stock
-
-
0
-
Proceeds from issuance of common stock in connection with follow-on offering, net of issuance costs
435,240
-
-
0
Proceeds from issuance of common stock in connection with at-the-market offering program, net of issuance costs
0
9,750
14,750
0
Proceeds from issuance of common stock in connection with follow-on offering, net of issuance costs
-
-
296,382
-
Payment of deferred offering costs in connection with shelf registration
283
171
69
0
Proceeds from issuance of private placement, net-Series ANon Voting Convertible Preferred Stock
-
-
0
-
Proceeds from issuance of private placement, net-Common Stock
-
-
0
-
Payment of contingent value rights liability
-
-
0
5,251
Payments related to contingent value rights liability
22,933
-
-
-
Proceeds from employee stock option exercises and employee stock plan purchases
20,579
2,676
1,749
491
Other financing cash flows
-
-
0
-
Net cash provided by financing activities
432,603
12,255
312,812
-4,643
Effect of exchange rate on cash, cash equivalents, and restricted cash
-
-
0
0
Net increase (decrease) in cash and cash equivalents
64,822
11,464
20,824
-16,762
Beginning of period
64,897
64,897
-
89,423
End of period
162,007
97,185
-
64,897
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
common stock in...
$435,240K
Proceeds from employee
stock option...
$20,579K
(1830.49%↑ Y/Y)
Net cash provided by
financing activities
$432,603K
(50437.73%↑ Y/Y)
Canceled cashflow
$23,216K
Net increase
(decrease) in cash and cash...
$64,822K
(934.90%↑ Y/Y)
Canceled cashflow
$367,781K
Payments related to
contingent value rights...
$22,933K
Payment of deferred
offering costs in...
$283K
(204.30%↑ Y/Y)
Proceeds from maturities
and sales of...
$109,439K
(-38.60%↓ Y/Y)
Proceeds from sale of
in-process research and...
$40,000K
(471.43%↑ Y/Y)
Stock-based compensation
$13,512K
(-25.91%↓ Y/Y)
Change in fair value of
cvr liability
-$4,603K
(-355.72%↓ Y/Y)
Interest proceeds from
maturities of zero coupon...
$311K
(-82.33%↓ Y/Y)
Accounts payable
$30K
(-99.02%↓ Y/Y)
Net cash (used in)
provided by investing...
-$297,904K
(-477.39%↓ Y/Y)
Net cash used in
operating activities
-$69,877K
(20.19%↑ Y/Y)
Canceled cashflow
$149,439K
Canceled cashflow
$18,456K
Purchases of marketable
securities
$447,343K
(320.78%↑ Y/Y)
Gain on sale of
in-process research and...
$40,000K
(300.00%↑ Y/Y)
Net loss
-$36,200K
(55.58%↑ Y/Y)
Prepaid expenses and
other assets
$5,608K
(48.20%↑ Y/Y)
Accrued and other
liabilities
-$3,428K
(58.69%↑ Y/Y)
Net accretion of
discount on marketable...
$3,093K
(-33.56%↓ Y/Y)
Related party accounts
payable
-$4K
(99.30%↑ Y/Y)
Buy us a coffee
Spyre Therapeutics, Inc. (SYRE)
Spyre Therapeutics, Inc. (SYRE)